In addition, tumor response as assessed by TRG according to Dworak et al. [15] was significantly associated with the incidence of TF in the overall cohort and when grouped by neoadjuvant treatment approach (Table S2, Figures S8–S11), and did not differ significantly between neoadjuvant treatment approaches, either (Table S3, Figures S12–S14). The gene discussed is TF; the disease is neoplasm.